Category: 386704-04-7

On January 1, 2018, Akama, Tsutomu; Zhang, Yong-Kang; Freund, Yvonne R.; Berry, Pamela; Lee, Joanne; Easom, Eric E.; Jacobs, Robert T.; Plattner, Jacob J.; Witty, Michael J.; Peter, Rosemary; Rowan, Tim G.; Gillingwater, Kirsten; Brun, Reto; Nare, Bakela; Mercer, Luke; Xu, Musheng; Wang, Jiangong; Liang, Hao published an article.Product Details of 386704-04-7 The title of the article was Identification of a 4-fluorobenzyl L-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT). And the article contained the following:

Novel L-valinate amide benzoxaboroles and analogs were designed and synthesized for a structure-activity-relationship (SAR) investigation to optimize the growth inhibitory activity against Trypanosoma congolense (T. congolense) and Trypanosoma vivax (T. vivax) parasites. The study identified 4-fluorobenzyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate (5, AN11736), which showed IC50 values of 0.15 nM against T. congolense and 1.3 nM against T. vivax, and demonstrated 100% efficacy with a single dose of 10 mg/kg against both T. congolense and T. vivax in mouse models of infection (IP dosing) and in the target animal, cattle, dosed i.m. AN11736 has been advanced to early development studies. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Product Details of 386704-04-7

The Article related to valinate amide benzoxaborole analog preparation trypanosoma congolense vivax, benzoxaborole, cattle, lead optimisation, protozoan, sar, trypanosomiasis, Pharmacology: Structure-Activity and other aspects.Product Details of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Formica, Michele; Sorin, Geoffroy; Farley, Alistair J. M.; Diaz, Jesus; Paton, Robert S.; Dixon, Darren J. published an article in 2018, the title of the article was Bifunctional iminophosphorane catalysed enantioselective sulfa-Michael addition of alkyl thiols to alkenyl benzimidazoles.Formula: C7H6F3NO And the article contains the following content:

The first enantioselective sulfa-Michael addition of alkyl thiols to alkenyl benzimidazoles, enabled by a bifunctional iminophosphorane (BIMP) organocatalyst, was described. The iminophosphorane moiety of the catalyst provided the required basicity to deprotonate the thiol nucleophile while the chiral scaffold and H-bond donor control facial selectivity. The reaction was broad in scope with respect to the thiol and benzimidazole reaction partners with the reaction proceeding in up to 98% yield and 96 : 4 er. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Formula: C7H6F3NO

The Article related to alkenyl benzimidazole alkanethiol iminophosphorane organocatalyst enantioselective sulfa michael addition, alkylthio alkyl benzimidazole preparation, Aliphatic Compounds: Ethers and Sulfides and other aspects.Formula: C7H6F3NO

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On December 24, 2020, Ang, Chee Wei; Tan, Lendl; Sykes, Melissa L.; AbuGharbiyeh, Neda; Debnath, Anjan; Reid, Janet C.; West, Nicholas P.; Avery, Vicky M.; Cooper, Matthew A.; Blaskovich, Mark A. T. published an article.Formula: C7H6F3NO The title of the article was Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility. And the article contained the following:

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting addnl. efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal Ph group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Formula: C7H6F3NO

The Article related to structure antitubercular antiparasitic nitroimidazo pyrazinone derivative preparation, Placeholder for records without volume info and other aspects.Formula: C7H6F3NO

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On December 24, 2020, Ang, Chee Wei; Tan, Lendl; Sykes, Melissa L.; AbuGharbiyeh, Neda; Debnath, Anjan; Reid, Janet C.; West, Nicholas P.; Avery, Vicky M.; Cooper, Matthew A.; Blaskovich, Mark A. T. published an article.Formula: C7H6F3NO The title of the article was Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility. And the article contained the following:

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting addnl. efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal Ph group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Formula: C7H6F3NO

The Article related to structure antitubercular antiparasitic nitroimidazo pyrazinone derivative preparation, Placeholder for records without volume info and other aspects.Formula: C7H6F3NO

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On March 31, 2016, Cai, Jiaqiang; Colandrea, Vincent; Crespo, Alejandro; Debenham, John; Du, Xiaoxing; Guiadeen, Deodialsingh; Liu, Ping; Liu, Rongqiang; Madsen-Duggan, Cristina B.; McCoy, Joshua G.; Quan, Weiguo; Sinz, Christopher; Wang, Liping published a patent.Related Products of 386704-04-7 The title of the patent was Inhibitors of HIF prolyl hydroxylase for use in enhancing erythropoietin production and treatment of anemia. And the patent contained the following:

The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Related Products of 386704-04-7

The Article related to inhibitor hif prolyl hydroxylase erythropoietin anemia therapy, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On September 22, 2016, Conn, P. Jeffrey; Lindsley, Craig W.; Emmitte, Kyle A.; Felts, Andrew S.; Bollinger, Katrina A. published a patent.Formula: C7H6F3NO The title of the patent was Pyridine derivatives as negative allosteric modulators of metabotropic glutamate receptor 2 and their preparation. And the patent contained the following:

Described are pyridine derivatives of formula I as neg. allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer’s disease, or autism spectrum disorders in a subject. Compounds of formula I wherein R1 is aryl, heteroaryl, heterocyclyl and cycloalkyl; R2a and R2b are independently H, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl and C1-4 haloalkoxy; R3 is X-(C(R5)2)0-2-Z-(C(R5)2)0-2-N(R6)2, X-(C(R5)2)0-2-Z-(C(R5)2)0-2-Y-A, A’-X-(C(R5)2)0-2-Z-(C(R5)2)0-2-N(R6)2, etc.; X, Y and Z are independently C(R5)2, O, S, CO, OCO, etc.; each R5 are independently H, F, C1-4 alkyl, C1-4 alkoxy, etc.; each R6 are independently C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, C1-6 heteroalkyl and heterocyclyl; N(R6)2 may be taken together form heterocyclyl; A and A’ are independently (un)substituted aryl, (un)substituted heteroaryl, (un)substituted cycloalkyl and (un)substituted heterocyclyl; R4 is CONH2 and CN; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). The invention compounds were evaluated for their mGlu2 receptor modulatory activity. From the assay, it was determined that compound II exhibited IC50 value of 6850 nM and a maximum response of 5.12 %. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Formula: C7H6F3NO

The Article related to pyridine preparation mglu2 receptor neg allosteric modulator, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Formula: C7H6F3NO

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On May 2, 2013, Bayburt, Erol K.; Clapham, Bruce; Cox, Phil B.; Daanen, Jerome F.; Gomtsyan, Arthur; Kort, Michael E.; Kym, Philip R.; Voight, Eric A.; Schmidt, Robert G.; Dart, Michael J.; Gfesser, Gregory published a patent.Application of 386704-04-7 The title of the patent was Preparation of (cyclobutyl)(pyridinyl)methanol derivatives as TRPV3 modulators. And the patent contained the following:

Title compounds I [each occurrence of Ra and Rb independently = H, (un)substituted alkyl, haloalkyl, halogen, OH, O(alkyl), or phenyl; q = 0-2; X3 = O; X4 = bond or (CH2)m; X5 = (CH2)n; m and n are each 1; each Z1 = alkyl, oxo, halogen, haloalkyl, etc.; p = 1-4; X1 = OH; X2 = H; G1 = (un)substituted aryl, heteroaryl, cycloalkyl, heterocycle, or cycloalkenyl; G2 = aryl, heteroaryl, cycloalkyl, heterocycle, or cycloalkenyl], and their pharmaceutically acceptable salts, are prepared Compounds of the invention were evaluated for ability to antagonize the activation of recombinant human TRPV3 using FLIPR Tetra cellular screening. Thus, e.g., II was prepared in a multi-step synthesis and had IC50 value of 0.19 nM as human TRPV3 antagonist. The invention compounds and combination with other therapeutic agent are useful for treating conditions such as pain and inflammation. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application of 386704-04-7

The Article related to methanol cyclobutyl pyridinyl preparation trpv3 modulator pain inflammation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Application of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On October 8, 2021, Wang, Bingzhi; Yang, Xingxing; Yan, Yiyong; Xu, Wenjian; Fu, Hui; Zeng, Chuyi; Huang, Yongjian; Liu, Yunwang; Wang, Shuishu published a patent.Category: alcohols-buliding-blocks The title of the patent was Preparation of sulfoxaflor hapten, artificial antigen and antibody for immunodetection of sulfoxaflor. And the patent contained the following:

The present invention relates to the preparation of sulfoxaflor hapten, artificial antigen and antibody for immunodetection of sulfoxaflor. In particular, the sulfoxaflor hapten I (wherein, n = 1, 2, 3, 4, or 5) was prepared The inventive hapten is coupled with the carrier protein to prepare artificial antigens, and the artificial antigens are used to immunize animals to obtain sulfoxaflor antibodies, the sulfoxaflor hapten, antigen, and antibody is used in immunol. detection, the inventive method provides a gold chromatog. detection device which can quickly and accurately detect sulfoxaflor residue content in vegetables or fruits, can meet regulators, on-site supervision and law enforcement detection mechanism needs, uses easily available chem. reagents, has simple operation process, high reaction yield and low detection cost.; the inventive detection method has high degree, high specificity, low cost, simple operation, short detection time and long shelf life. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Category: alcohols-buliding-blocks

The Article related to sulfoxaflor hapten preparation artificial antigen antibody immunodetection, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Category: alcohols-buliding-blocks

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On April 5, 2012, Bae, Sung Jin; Yi, Han Ju; Hwang, Sun Gwan; Jeong, Mo Ses; Yoon, Yeo Jin; Chae, Sang Mi; Park, Joo Young; Ryu, Eun Ju published a patent.Application of 386704-04-7 The title of the patent was Cyclohexane derivatives as NO production inhibitors and their preparation and use for the treatment of pain. And the patent contained the following:

The invention relates to cyclohexane derivatives of formula I, which are inhibitors of nitric oxide production and which are useful in the treatment of pain. Compounds of formula I wherein Ar is (un)substituted Ph, (un)substituted pyridine and (un)substituted pyridine N-oxide; X is O, C(O)O, NH, etc.; Y is CH2, O and NH and derivatives; A is O and NH; Q is CH and N; m is 0 to 2; n is 0 and 1; and pharmaceutically acceptable salts, isomers, solvates and hydrates thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their NO production inhibitory activity. From the assay, it was determined that compound II exhibited IC50 values in the range 7.5 – 9.9 μM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application of 386704-04-7

The Article related to cyclohexane preparation nitric oxide production inhibitor treatment pain, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Application of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On September 2, 2014, Bae, Sung Jin; Yi, Han Ju; Hwang, Sun Gwan; Jeong, Mo Ses; Yoon, Yeo Jin; Chae, Sang Mi; Park, Joo Young; Ryu, Eun Ju published a patent.Formula: C7H6F3NO The title of the patent was Methylcyclohexane derivatives and uses thereof. And the patent contained the following:

A novel methylcyclohexane derivative, and a pharmaceutical composition including the same that is effective for the prevention or treatment of pain. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Formula: C7H6F3NO

The Article related to cyclohexane preparation nitric oxide production inhibitor treatment pain, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Formula: C7H6F3NO

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts